Filippo Branzanti

Bologna, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Correction to: Modern and multidisciplinary care in polycythemia vera.

Correction to: Modern and multidisciplinary care in polycythemia vera.

Journal: Annals of hematology
Published: July 25, 2026

SOHO State of the Art Updates and Next Questions | Predictive Markers for Ruxolitinib in Myelofibrosis.

SOHO State of the Art Updates and Next Questions | Predictive Markers for Ruxolitinib in Myelofibrosis.

Journal: Clinical lymphoma, myeloma & leukemia
Published: June 26, 2026

A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib.

A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib.

Journal: Blood advances
Published: February 27, 2026

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.

Journal: Blood advances
Published: February 27, 2026

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.

Journal: Cancer
Published: February 19, 2026

Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.

Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.

Journal: Cancer
Published: December 16, 2025

Modern and multidisciplinary care in polycythemia vera.

Modern and multidisciplinary care in polycythemia vera.

Journal: Annals of hematology
Published: December 14, 2025

Modern and multidisciplinary care in polycythemia vera.

Modern and multidisciplinary care in polycythemia vera.

Journal: Annals of hematology
Published: December 14, 2025

Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison.

Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison.

Journal: Annals of hematology
Published: November 14, 2025

Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Journal: Blood
Published: August 26, 2025

Neutrophil to lymphocyte ratio at diagnosis predicts venous thrombosis in prefibrotic primary myelofibrosis: results from a multicenter cooperative study.

Neutrophil to lymphocyte ratio at diagnosis predicts venous thrombosis in prefibrotic primary myelofibrosis: results from a multicenter cooperative study.

Journal: Annals of hematology
Published: July 23, 2025

Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib.

Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib.

Journal: Cancer
Published: May 05, 2025
Showing 1-12 of 23

Last Updated: 09/26/2026